arrow
T

Toshiyuki Ishiba

Department of Breast Surgery
H指数:10
被引数:483

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017

更正:原发灶与转移灶在药物疗效和预后方面的差异——一项对de novo IV期乳腺癌III期临床试验JCOG1017的探索性分析

2026-05-290
OAAI
Primary tumour resection reduces the risk of major local morbidity in de novo stage IV breast cancer: secondary data analysis from the JCOG1017 randomized controlled trial

原发肿瘤切除可降低新诊断IV期乳腺癌的主要局部并发症风险:来自JCOG1017随机对照试验的二次数据分析

bjs
IF0
2026-05-010
PRE
Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017

原发性与转移部位在de novo IV期乳腺癌中药物疗效和预后的差异:一项JCOG1017 III期试验的探索性分析

2026-04-160
OAAI
Clinical complete response and predictive factors in HER2-positive early breast cancer treated with neoadjuvant chemotherapy aimed at omission of surgery: an exploratory analysis of the JCOG1806 trial
2026-01-220
OAAI
A randomized controlled trial of metastasis-directed therapy for oligometastases in breast cancer: OLIGAMI trial (JCOG2110)

乳腺癌寡转移的转移导向疗法随机对照试验:OLIGAMI试验(JCOG2110)

2026-01-010
PRE
A multi-institutional dummy run on segmentation variability and plan quality of stereotactic body radiotherapy for oligometastatic disease

多机构模拟运行评估寡转移性疾病立体定向体部放射治疗的分割变异性和计划质量

2025-11-010
OAAI
Impact of estrogen receptor positivity for adjuvant endocrine therapy in luminal T1a/bN0M0 breast cancer: A multi-institutional retrospective observational study

雌激素受体阳性对luminal T1a/bN0M0乳腺癌辅助内分泌治疗的影响:一项多中心回顾性观察性研究

2024-09-010
PRE
A Randomized Controlled Trial of Metastasisdirected Therapy for Oligometastases in Breast Cancer (OLIGAMI trial; JCOG2110)
2024-05-020
PRE
The Prognostic Impact of Adjuvant Endocrine Therapy by Age for Patients with Small Estrogen Receptor-Positive (ER plus ), Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer
2024-05-020
PRE
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
2023-09-094
OAAI